The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure.
 
Stefanie L. Groenland
No Relationships to Disclose
 
Ruben A.G. van Eerden
No Relationships to Disclose
 
Stijn L.W. Koolen
Speakers' Bureau - Novartis; Pfizer
Research Funding - Cristal Therapeutics (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Dirk Jan A.R. Moes
Consulting or Advisory Role - Chiesi; Sandoz
Research Funding - Chiesi (Inst)
 
Alex Imholz
No Relationships to Disclose
 
Sofie Wilgenhof
No Relationships to Disclose
 
Winette T.A. Van Der Graaf
Leadership - InHealth Group (I)
Honoraria - Bayer (I)
Consulting or Advisory Role - Bayer (I); Bayer (Inst); SpringWorks Therapeutics (Inst)
Speakers' Bureau - Bayer (I)
 
Hans Gelderblom
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst)
 
Jos H. Beijnen
Employment - Modra Pharmaceuticals
Stock and Other Ownership Interests - Modra Pharmaceuticals
Honoraria - Modra Pharmaceuticals
Research Funding - Astex Pharmaceuticals (Inst); Modra Pharmaceuticals (Inst); Neon Therapeutics (Inst); PharmaMar (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent dealing with the pharmaceutical formulation of oral taxanes (Inst)
 
Ron H.J. Mathijssen
Speakers' Bureau - Novartis
Research Funding - Astellas Pharma (Inst); Bayer Holding (Inst); Boehringer Ingelheim (Inst); Cristal Therapeutics (Inst); Pamgene (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Alwin Huitema
Research Funding - Merus NV (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Neeltje Steeghs
Research Funding - AB Science (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cytovation (Inst); Deciphera (Inst); Genentech (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)